Recombinant Chimeric Antigens for Scrub Typhus Diagnostics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and vaccine development for scrub typhus face challenges due to the high cost and complexity of producing and purifying Orientia tsutsugamushi antigens, as well as strain variation and limited availability of effective vaccines, which complicates the diagnosis and treatment of the disease.
Innovation Solution
Development of recombinant chimeric antigens comprising modified and unmodified reactive polypeptide fragments of the 56 kDa protein from multiple strains of Orientia tsutsugamushi, which can be used in serodiagnostic assays and vaccine formulations to provide broad cross-reactivity and improved protection against scrub typhus.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional Orientia tsutsugamushi antigens are used for diagnostic assays and vaccine development, then broad cross-reactivity and protection can be achieved, but the cost and complexity of production and purification increase significantly
Solution Approach 1:
The invention segments the 56 kDa protein into smaller polypeptide fragments (e.g., amino acid residues 80-275, or specific domains I-IV). These fragments are then genetically fused with carrier proteins or adjuvants to create chimeric antigens. This segmentation allows for simplified production through recombinant DNA technology while maintaining the immunogenic and diagnostic properties of the original protein, thereby reducing production complexity while preserving cross-reactivity.
Solution Approach 2:
The invention creates composite antigens by fusing polypeptide fragments of the 56 kDa protein with carrier proteins (e.g., keyhole limpet hemocyanin, bovine serum albumin) or adjuvants. These chimeric constructs combine the antigenic determinants of the 56 kDa protein with the immunogenic properties of the carrier, achieving broad cross-reactivity and enhanced immunogenicity while enabling cost-effective production through standardized recombinant expression systems.
2Ease of manufacture
If recombinant chimeric antigens are developed to reduce cost and complexity, then production becomes more feasible, but the reactivity with multiple strains must be maintained
Solution Approach 1:
The invention designs polypeptide fragments that target universal conserved regions of the 56 kDa protein across multiple Orientia tsutsugomushi strains. By focusing on amino acid sequences that are highly conserved among different strains (e.g., domains I-IV), the chimeric antigens achieve universal recognition by antibodies against various strains. This multi-functional design ensures that a single recombinant construct can serve as both a diagnostic tool and vaccine candidate for broad strain coverage, maintaining reliability while enabling ease of manufacture through standardized production.
3Adaptability or versatility
If multiple strains of Orientia tsutsugamushi are used to ensure broad protection, then vaccine efficacy improves, but the complexity of producing and purifying antigens from multiple sources increases
Solution Approach 1:
The invention merges polypeptide fragments from multiple Orientia tsutsugamushi strains into single chimeric antigen constructs. Instead of producing separate antigens from each strain, the conserved regions from multiple strains are combined into one or a few fusion proteins. This merging approach maintains broad strain coverage and adaptability while dramatically simplifying production and purification, as only the chimeric constructs need to be produced through recombinant expression rather than multiple separate antigen preparations.
Data Source
AI summary
Recombinant chimeric antigens comprising unmodified and modified reactive polypeptide fragments of expressed product of the recombinant 56 kDa proteins of multiple strain of scrub typhus, such as Karp, Kato (Ktr56), Gilliam (Gmr56), and TA763 (TAr56). The invention is useful for detecting prior exposure to a number of strains of scrub typhus, based on the strength of reaction toward the chimeric protein and as a component in vaccine formulations and production of immune globulins for passive prophylaxis and immunity in subjects against heterologous infections.